Howe Jolanda's Form 4 filing
Mirum Pharmaceuticals, Inc. (MIRM) · filed Mar 18, 2025
- Accession no.
- 0001415889-25-008558
- Filed
- Mar 18, 2025
- Trade date
- Mar 15-17, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.55M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Howe JolandaCIK 0001974200 | Officer (SVP, GLOBAL CONTROLLER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2025 | Common Stock | MOption exerciseAcquired | +5,315 | –F1 | – | 9,547 | Direct | |
| Mar 17, 2025 | Common Stock | SSaleDisposed | −2,900 | $44.21 | −$128,209 | 6,647 | Direct | |
| Mar 17, 2025 | Common Stock | MOption exerciseAcquired | +52,900 | $2.94 | +$155,526 | 59,547 | Direct | |
| Mar 17, 2025 | Common Stock | SSaleDisposed | −50,111 | $44.33F4 | −$2,221,420.63 | 9,436 | Direct | |
| Mar 17, 2025 | Common Stock | SSaleDisposed | −2,789 | $44.75F5 | −$124,807.75 | 6,647 | Direct | |
| Mar 17, 2025 | Common Stock | SSaleDisposed | −1,806 | $44.36F6 | −$80,114.16 | 4,841 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2025 | Common Stock | MOption exerciseDisposed | −5,315 | $0.00 | $0 | 2,658 | Direct | |
| Mar 17, 2025 | Common Stock | MOption exerciseDisposed | −52,900 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Referenced by the price of 1 transaction in Table I.
- F4
The weighted average sale price for the transaction reported was $44.33410, and the range of prices were between $43.695 and $44.695. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.
- F5
The weighted average sale price for the transaction reported was $44.74811, and the range of prices were between $44.70 and $44.84. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.
- F6
The weighted average sale price for the transaction reported was $44.35923, and the range of prices were between $43.81 and $44.71. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.